STOCK MARKET BSE NSE

Covishield to cost Rs 400 a dose for states, Rs 600 for private hospitals

In a statement, SII, which is manufacturing Covishield following a tie-up with AstraZeneca-Oxford University, announced the new prices.

Published: 21st April 2021 07:03 PM  |   Last Updated: 21st April 2021 07:03 PM   |  A+A-

A health worker holds up a Covishield vial. (Photo | EPS)

Express News Service

NEW DELHI: Two days after the Centre liberalised the Covid vaccination policy allowing states and private hospitals to procure 50% of all vaccine supplies, Serum Institute of India (SII) said that Covishield would be sold at Rs 400 per dose to states and Rs 600 per dose to private hospitals.

Though not said explicitly, it implies that people who go for vaccinations in private hospitals may have to pay a higher price per dose of Covishield, as Rs 600 per dose being the procurement price, private hospitals may apply additional charges.

In vaccination centres run by the Union government, the vaccine will continue to be administered for free to those above 45 years while states will take individual calls for vaccination centres run by them.

 On Monday, the Narendra Modi government, while announcing that starting May 1, Covid19 vaccination will be opened for all above 18 years in India, also said that half of the vaccine supplied can be procured by the states and private hospitals directly and the vaccine makers can sell them at pre-declared prices.  

Though a statement by the company did not mention the change in price to the Centre, in an interview with a TV channel, the company CEO Adar Poonawalla also said that the vaccine per dose will now cost a re-negotiated Rs 400 per dose to the Centre.

As of now, the Union government is buying the vaccine at Rs 150 per shot but Poonawalla said that the company was making losses at this rate.

ALSO READ | Covaxin found to be effective against most Covid variants; expert says the result "not surprising"

Of over 13 crore vaccine doses administered in the country so far, Covishield’s share has been 85-90%, largely due to significantly higher production capacity of SII, in comparison to Bharat Biotech, the manufacturer of Covaxin, the only other Covid19 vaccine available in the country presently.

In a statement, SII, which is manufacturing Covishield following a tie-up with AstraZeneca-Oxford University, announced the new prices.

The firm said that Covishield will still be more affordable than foreign jabs, which cost anywhere from Rs 750 to Rs 1,500 per shot and added that supplying the vaccine independently to corporates would be challenging and urged firms and individuals to access the shots through states and private hospitals.

“...owing to the complexity, and urgency of the situation it is challenging to supply it independently to each corporate entity," said the company in a statement. “We would urge all corporate and private individuals to access the vaccines through the state facilitated machinery and private health systems”

It also said that the vaccine may be available in the retail market 4-5 months from now.

Meanwhile many have criticised the government for leaving the price control in the hands of private players. “It is not clear how SII is able to declare the price at which it will be selling its vaccine to state governments without engaging in procurement processes,” Malini Aisola of the All India Drug Action Network told The New Indian Express.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp